Podcast | July 16, 2021

Australia: Growing Clinical Trials Even In Pandemic's Wake

Source: DIA
doctor clinical trial meeting iStock-986569806

DIA Global Forum Australia/New Zealand Regional Editor Richard Day (University of New South Wales, Medicine, St. Vincent’s Hospital) and John Skeritt, Head of Australia’s Therapeutic Goods Administration (TGA), discuss regulatory strategies and other initiatives designed to help nurture clinical research and product development in Australia post-pandemic. With “Australia having had many fewer cases than comparable countries, we've actually become in very short time a very attractive global destination for clinical trials. And, in fact, because of our low numbers, the demand has significantly increased,” John explains. “For medicines, biologicals, and devices, for example, in the last six months of last year, July to December 2020, we actually had a 17% increase in the number of clinical trials, even though COVID was rife in some parts of Australia at that time.”

LISTEN TO THE PODCAST!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: